Specifically, SPTBN2 is not only a potential prognostic indicator for PAAD patients, but also correlates with immune cell infiltration levels, immune checkpoint expression, and immunotherapy response, and is a potential immunotherapeutic biomarker for PAAD that can be used to select PAAD patients who may benefit from ICB therapy. This evidence concerns the gene SPTBN2 and pancreatic adenocarcinoma.